We partner with several multiplex platforms companies. Each brings a unique set of offerings and skills. Together, we can offer complete solutions, test and develop in a way that no individual company can offer.
Low volume liquid handling: M2-Automation microarray spotters provide the precision you need for diagnostic applications like lateral flow, MTPs, micro-electronics, biosensors, modified glass-slide surfaces, cell spotting assays, MALDI-MS, LC-MS and Lab on a chip.
Spotting technologies: The portfolio encompasses contact and non-contact liquid handling solutions, from low volume pico- and nanolitre microarray dispenser, based on unique piezo- and solenoid technology, to microliter volumes.
The SnapChip is more than a simple multiplex, it’s multiple singleplex!
In the SnapChip microarray-to-microarray approach, the colocalization of capture and detection antibodies efficiently eliminates cross-reaction as detection antibodies are physically isolated from each other. It is also highly customizable and there are no incompatibility issues, as no analytes are mixed together. As a result, the assay optimization process is simplified.
This is the fastest approach to generating good data for protein biomarkers panels. In the realm of multiplex platforms companies, ParallexBio represents a unique and most innovative approach to deal with a very real problem in high multiplex tests.
GENSPEED Biotech was founded in 2016 as a spin-off company of Greiner Bio-One. We develop, produce and distribute IVD-certified rapid testing solutions based on the patented GENSPEED® technology. While there are many multiplex platforms companies, GENSPEED offers a ready-to-go system. Just add your biology and you have a field useable test.
Creator of the latest innovation in label-free biomolecular interaction analysis. Introducing a compact, robust, low-cost, fully-automated, and easy-to-use research instrument with versatile and inexpensive consumables. Analytes can include: proteins, nucleic acids, peptides, and small molecules. Based on the IRIS technology, the platform offers high multiplexing, up to hundreds of probes, quantitative measurements, high repeatability, and molecular sensitivity down to 250 Da.
This new multiplex platforms company brings about many years of academic research into a most promising label-free detection modality.